Steven Cohen’s Galmed Pharmaceuticals GLMD Stock Holding History

Steven Cohen’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-80	Closed	-$1.56M	–	1057
2018 Q3	$1.56M	Sell	80 -355	-82%	-$6.65M	0.01%	787
2018 Q2	$7.45M	Buy	+435	New	+$5.04M	0.03%	511

Other funds holding GLMD

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Steven Cohen's GLMD Position: Q4 2018 in Review

Steven Cohen sold out of Galmed Pharmaceuticals (GLMD) in Q4 2018, closing a stake of 80 shares — an estimated $1.56M sold.

Steven Cohen first reported a position in GLMD in Q2 2018 and held it in 2 quarters. The position peaked at $7.45M in Q2 2018. 37 funds tracked by Wall St. Rank hold GLMD as of Q4 2018.

Steven Cohen reported no remaining Galmed Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Steven Cohen sold 80 Galmed Pharmaceuticals shares in Q4 2018, an estimated $1.56M.
Steven Cohen first reported a position in Galmed Pharmaceuticals in Q2 2018 and held it in 2 quarters.
Steven Cohen's Galmed Pharmaceuticals position peaked at $7.45M in Q2 2018.
37 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2018.

Based on Point72 Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.